Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2018

View Archived Issues

Aging microbiome triggers immunity changes, insulin resistance

Leo Pharma and PellePharm collaborate to advance innovative therapies for rare skin diseases

Variations of variations could give new insights into AD, brain organization

Medivir nominates MIV-828 as candidate drug for AML and hematological malignancies

Zenith Epigenetics announces collaboration with Pfizer in breast cancer clinical trial

A next-generation cyclin-dependent kinase inhibitor from Pfizer presented

YHO-1701 demonstrates promising in vivo activity as monotherapy or in combinations

Novel bioactive lipid nanoparticle demonstrates efficacy in multiple human tumor models

Synthetic announces successful completion of end-of-phase II meeting with FDA regarding ribaxamase

EVT-601, a first-in-class allosteric FGFR antagonist

Novartis AG patents new DNA gyrase inhibitors as antibacterials

FDA grants accelerated approval to Venclexta for newly diagnosed AML

Axxam SpA presents P2X7 receptor antagonists

FDA approves Daurismo for newly diagnosed AML ineligible for intensive chemotherapy

Discovery and characterization of novel potent and selective CD73 inhibitor A-001202

MDM2 degraders for anticancer therapy presented

IBT amends planned phase III protocol for IBP-9414

Final phase I/Ib study results with Pulmazole support advancement to phase II

AU-15506, a highly potent, selective inhibitor of CDK12 with oral efficacy in a TNBC model

GlaxoSmithKline begins first-in-human study of GSK-3368715 in solid tumors and DLBCL

New phase II/III study in Hong Kong investigates JCM-16021 for diarrhea-predominant IBS

REALIST study explores use of mesenchymal stem cells to treat ARDS

Arcus presents novel small-molecule CD73 inhibitors for orally bioavailable cancer therapy

Phase I results demonstrate encouraging efficacy for D2C7-IT in malignant glioma

HitGen and Biogen form drug discovery research collaboration